# Genesis Therapeutics

> AI molecular discovery company for small-molecule drug design (now Genesis Molecular AI).

## Why it is interesting

Genesis pioneered physics-informed generative AI for drug discovery; a16z led seed and co-led a $200M Series B with Menlo Ventures before the company rebranded to Genesis Molecular AI.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, ai-ml
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (2020): $52M led by Rock Springs with Menlo Ventures (/fund/menlo-ventures) and a16z seed lead (BioSpace)
- Series B (Aug 2023): $200M co-led by a16z Bio+Health (/fund/andreessen-horowitz) and Menlo Ventures (BusinessWire)
- Rebranded to Genesis Molecular AI; pharma deals with Genentech and Eli Lilly

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/menlo-ventures

---
Source: https://venturecapitaltracker.com/startup/genesis-therapeutics